[
  {
    "ts": null,
    "headline": "Moderna Inc. stock outperforms competitors on strong trading day",
    "summary": "Moderna Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=29083e516322e431c6b4239ff73092b70666ee91244cb87ab1d6a93843d28bfe",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733934720,
      "headline": "Moderna Inc. stock outperforms competitors on strong trading day",
      "id": 131952485,
      "image": "",
      "related": "MRNA",
      "source": "MarketWatch",
      "summary": "Moderna Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=29083e516322e431c6b4239ff73092b70666ee91244cb87ab1d6a93843d28bfe"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates",
    "summary": "The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections.",
    "url": "https://finnhub.io/api/news?id=75ede7b1201b5c8acf28721014ac424b2e2a29fee1b612ae1595eb810bc7640e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733930700,
      "headline": "FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates",
      "id": 131923511,
      "image": "https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections.",
      "url": "https://finnhub.io/api/news?id=75ede7b1201b5c8acf28721014ac424b2e2a29fee1b612ae1595eb810bc7640e"
    }
  },
  {
    "ts": null,
    "headline": "Moderna reinstated with an Underperform at BofA",
    "summary": "BofA reinstated coverage of Moderna (MRNA) with an Underperform rating and $41 price target calling it “a tough time to be a vaccines company,” citing COVID revenue stream uncertainty even if RFK Jr. doesn’t become head of the HHS. The firm also has “mixed views” on the company’s current late-stage pipeline, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Rea",
    "url": "https://finnhub.io/api/news?id=1b6b76a9d39d42fe7a144492446d74891ac2c3dedbc6eee6a62318b1f2abb708",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733918758,
      "headline": "Moderna reinstated with an Underperform at BofA",
      "id": 131930582,
      "image": "",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "BofA reinstated coverage of Moderna (MRNA) with an Underperform rating and $41 price target calling it “a tough time to be a vaccines company,” citing COVID revenue stream uncertainty even if RFK Jr. doesn’t become head of the HHS. The firm also has “mixed views” on the company’s current late-stage pipeline, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Rea",
      "url": "https://finnhub.io/api/news?id=1b6b76a9d39d42fe7a144492446d74891ac2c3dedbc6eee6a62318b1f2abb708"
    }
  }
]